We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Sensitive Clinical Marker Defined for Ulcerative Colitis Evolution

By LabMedica International staff writers
Posted on 20 Sep 2016
Print article
Image: The semi-quantitative Calprotectin 50 + 200 combo card test (Photo courtesy of CerTest Biotec).
Image: The semi-quantitative Calprotectin 50 + 200 combo card test (Photo courtesy of CerTest Biotec).
The two main subtypes of inflammatory bowel diseases (IBD), Crohn’s disease (CD) and ulcerative colitis (UC) are characterized by episodes of inflammatory activity and remission and determination of disease activity remains challenging, with most clinical scores correlating poorly with the inflammatory state.

Treatment of IBD patients has recently shifted from controlling symptoms to promoting endoscopic mucosal healing or deep remission and treatment promoting mucosal healing can slow the progression of the disease. In this context, laboratory biomarkers have gained importance in evaluating and predicting the response to therapy.

Scientists at the University of Chile (Santiago, Chile) prospectively recruited 26 patients grouped according to an endoscopic score and therapy response. Colonoscopic biopsies were collected at baseline and six months or when patients showed clinical activity. The protocol was reinitiated in patients requiring rescue therapy. Blood and stool were collected at baseline, one, three, six and 12 months.

Serum and intestinal ST2 (Interleukin 1 receptor-like 1) concentrations, as well as serum interleukin -33 (IL-33) levels were measured using an enzyme-linked immunosorbent assay (ELISA) kit for human ST2 or IL-33 (DuoSet, R&D Systems, Minneapolis, MN, USA). The ST2 detection assay is stable over time, with a detection limit of 20 pg/mL, while the IL-33 detection assay is less stable over time, with a detection limit of 23.4 pg/mL. The supernatant from the fecal samples were processed for the rapid semi-quantitative test Calprotectin 50+200 (CerTest Biotec S.L., Zaragoza, Spain). Mucosal ST2 detection was performed by immunofluorescence and the images captured using an Olympus confocal laser scanning biological microscope FV10i (Olympus America Inc., Melville, NY, USA).

The team reported that follow-up was completed in 24 patients. The statistically significant median and range of soluble sST2 levels varied from 173.5 pg/mL (136.6–274.0) to 86.5 pg/mL (54.6–133.2) in responders and 336.3 pg/mL (211.0–403.2) to 385.3 pg/mL (283.4–517.3) in non-responders at baseline and six months respectively. Soluble sST2 levels correlated with Mayo clinical and endoscopic subscore, mucosal ST2 and fecal calprotectin (FC) and showed a trend similar to that of FC in responders. Non-responders revealed an increased ST2 content, restricted to the lamina propria’s cellular infiltrate.

The authors concluded that during the follow-up, serial ST2 measurements decreased in those patients with a reduced endoscopic index at six months, indicating a positive response to therapy. In those patients, FC levels were also significantly decreased in direct correlation to sST2 levels. The accuracy of sST2 in endoscopic detection of UC strongly suggests its usefulness in monitoring relapse and outcome, as well as in identifying patients likely to benefit from a particular treatment. The study was published on August 28, 2016, in the journal BMC Gastroenterology.

Related Links:
University of Chile
R&D Systems
CerTest Biotec
Olympus America
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
25-OH-VD Reagent Kit
New
TORCH Infections Test
TORCH Panel

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.